Neurocrine Biosciences Inc. (NBIX)

100.83
NASDAQ : Health Technology
Prev Close 101.50
Day Low/High 100.49 / 102.50
52 Wk Low/High 64.72 / 125.59
Avg Volume 658.40K
Exchange NASDAQ
Shares Outstanding 91.58M
Market Cap 9.30B
EPS 0.20
P/E Ratio 505.60
Div & Yield N.A. (N.A)
Vote for the Best Biotech CEO of 2010

Vote for the Best Biotech CEO of 2010

Readers will decide who takes home the award for the Best Biotech CEO of 2010. Vote now!

5 Drug Stock Winners of 2010

5 Drug Stock Winners of 2010

Drug approvals, clinical trial wins and sales growth helped stocks like Amarin and Questcor to more than double this year.

Neurocrine CEO Discusses Q3 2010 Results - Earnings Call Transcript

Neurocrine CEO Discusses Q3 2010 Results - Earnings Call Transcript

Harbor Bio, Cypress Bio: Volume Movers

Several stocks trading below $5, including Harbor BioSciences, were poised to move on above-average volume Wednesday.

Neurocrine Biosciences, Inc. Q2 2010 Earnings Call Transcript

Neurocrine Biosciences, Inc. Q2 2010 Earnings Call Transcript

Discovery Labs, FelCor: Volume Movers

Several stocks, including Discovery Labs, were poised to move on above-average volume Thursday.

Neurocrine Licenses Drug to Abbott:BioBuzz

Neurocrine Licenses Drug to Abbott:BioBuzz

Abbott gains worldwide rights to elagolix for the treatment of endometriosis.

Abbott Goes After Endometriosis

Abbott Goes After Endometriosis

Abbott Labs and Neurocrine Biosciences will jointly develop and commercialize elagolix for the treatment of endometriosis-related pain.

Javelin Pharmaceuticals, FuelCell Energy: Midday Volume Plays

Several stocks trading near $5, including Javelin Pharmaceuticals, were moving on above-average volume Thursday.

Hanmi Financial, Neurocrine Biosciences: Midday Volume Plays

Several stocks trading near $5, including Hanmi Financial, were moving on above-average volume Wednesday.

EMC, Beazer Homes, AutoZone Among Big Movers

EMC, Beazer Homes, AutoZone, DiamondRock Hospitality among big market movers Tuesday

Neurocrine Biosciences, Sprint: Early Volume Plays

Several stocks trading near $5, including Sprint, were poised to move on above-average volume Tuesday.

Neurocrine Biosciences Inc. Q1 2010 Earnings Call Transcript

Neurocrine Biosciences Inc. Q1 2010 Earnings Call Transcript

General Moly, YM BioSciences: Early Volume Plays

Several stocks trading near $5 were moving on above-average volume during Friday's session.

Neurocrine's Elagolix Misses Main Study Goal

Patients treated for endometriosis with elagolix reported improved daily pelvic pain scores compared with placebo, but the difference wasn't statistically significant.

Biotech Clinical Trials to Watch in 2009

Biotech Clinical Trials to Watch in 2009

Senior Writer Adam Feuerstein provides a list of biotech and drug clinical trials expected to move stocks in 2009.

Single Drugmakers Seek Rich Partners

Single Drugmakers Seek Rich Partners

Scores of smaller biotech firms have unpartnered drugs in the pipeline, making them ripe for alliances or takeovers.

Biotech Mailbag: Avoid Nuvelo-ARCA Merger

The centerpiece of the newly combined company is Gencaro, an unimpressive heart failure drug.

Wedneday's Winners & Losers: Take-Two Takes Off

Wedneday's Winners & Losers: Take-Two Takes Off

The video-game publisher shrinks its losses.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Abiomed wins FDA approval for its ventricular support device.

Thursday's Health Winners & Losers

Biogen Idec falls.

No Relief for Sleepless Neurocrine Investors

No Relief for Sleepless Neurocrine Investors

The FDA again asks for more data on sleep-aid drug Indiplon.

Wednesday's Health Winners & Losers

Geron climbs on news of a $4 million milestone payment.

No Easy Fix for Pfizer

No Easy Fix for Pfizer

It can be done, but it will probably require some tough choices.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

This week: Biogen Idec and Neurocrine Biosciences.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

Arena Pharma faces an important safety check.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Cephalon slumps after posting lower-than-expected quarterly numbers.

Tuesday's Late Winners & Losers

Nerocrine Biosciences was among the late movers Tuesday in light trading.

Feuerstein's Biotech Mailbag

Feuerstein's Biotech Mailbag

This week, Bioenvision, Nuvelo and Neurocrine.

Top Trades Outside of Tech

Top Trades Outside of Tech

Consider putting your capital in more reliable corners of the market.

TheStreet Quant Rating: C+ (Hold)